In the current study, the investigators will evaluate intratumoral pharmacodynamic and
pharmacokinetic data associated with the administration of the HDACI, Panobinostat, among
recurrent GBM patients. In addition, this study will evaluate the safety and tolerability of
this agent, as well as evidence of anti-tumor activity in the patient population.